Mezzion Pharma Co.Ltd (140410) — Cash Flow-to-Debt Ratio
Mezzion Pharma Co.Ltd (140410) has a Cash Flow-to-Debt Ratio of -0.07x as of March 2026, meaning its operating cash flow of ₩-6.07 Billion could theoretically repay 0% of its total liabilities (₩83.41 Billion) in one year. See financial flexibility index of Mezzion Pharma Co.Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mezzion Pharma Co.Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Mezzion Pharma Co.Ltd across 12 annual periods. For the full cash flow conversion analysis, see Mezzion Pharma Co.Ltd operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Mezzion Pharma Co.Ltd (2012–2025)
Year-by-year debt coverage analysis for Mezzion Pharma Co.Ltd. Check Mezzion Pharma Co.Ltd (140410) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.59 Billion | ₩80.83 Billion | ▲ +69.0% |
| 2024 | -0.66x | ₩-18.49 Billion | ₩27.94 Billion | ▼ -84.4% |
| 2023 | -0.36x | ₩-11.02 Billion | ₩30.70 Billion | ▲ +17.4% |
| 2022 | -0.43x | ₩-12.07 Billion | ₩27.78 Billion | ▲ +39.0% |
| 2021 | -0.71x | ₩-15.07 Billion | ₩21.14 Billion | ▼ -81.8% |
| 2020 | -0.39x | ₩-7.38 Billion | ₩18.82 Billion | ▲ +69.9% |
| 2019 | -1.30x | ₩-20.88 Billion | ₩16.04 Billion | ▼ -6.3% |
| 2018 | -1.22x | ₩-21.72 Billion | ₩17.74 Billion | ▼ -93.4% |
| 2017 | -0.63x | ₩-13.21 Billion | ₩20.87 Billion | ▼ -349.0% |
| 2016 | -0.14x | ₩-6.08 Billion | ₩43.09 Billion | ▼ -422.4% |
| 2015 | 0.04x | ₩1.77 Billion | ₩40.52 Billion | ▼ -94.5% |
| 2012 | 0.79x | ₩3.14 Billion | ₩3.97 Billion | — |